1. Tildrakizumab showed sustained efficacy and safety for moderate-to-severe scalp psoriasis in a phase 3b trial.
2. Patients receiving tildrakizumab maintained improved response rates up to 52 weeks.
3. Quality of life measures, including the Dermatology Life Quality Index, demonstrated significant improvements. 
4. Adverse events were manageable, with serious adverse events reported in a small percentage of patients. 
5. Further studies are needed to validate the results in broader clinical practice.

Source: Journal of the American Academy of Dermatology.